Mode
Text Size
Log in / Sign up

Vacuum-assisted breast biopsy of B3 lesions shows 11.23% pooled proportion of malignant upgradesVacuum-assisted biopsy helps identify hidden cancer in breast lesions

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that VAB/VABB of B3 lesions shows a 11.23% malignant upgrade rate with very low certainty of evidence.

This meta-analysis evaluated the utility of vacuum-assisted breast biopsy (VAB/VABB) for the management of B3 lesions. The analysis included 844 B3 lesions from 5 full-text studies. The primary finding was a 11.23% pooled proportion of malignant upgrades in B3 lesions following diagnostic VAB/VABB (95% CI 7.22%-17.04%; 95% PI 4.56%-25.06%).

Secondary outcomes, including radiologic removal, absence of residual lesion, and recurrence-free outcomes post-VAE, ranged from 86.0% to 99.2%. However, these secondary outcomes were not pooled. The authors noted several limitations, including the incomplete retrieval of 8 publications and the fact that only one fully retrieved study provided reconstructable 2x2 data, which precluded a diagnostic meta-analysis or hierarchical model.

Clinical certainty for the primary observational outcomes is very low, and certainty for the single randomized comparison is low. The authors suggest that the evidence supports pathway-specific interpretation and multidisciplinary decision-making rather than establishing universal superiority over core needle biopsy or equivalence to surgical excision.

How this fits prior evidence

This meta-analysis addresses a gap in the management of B3 lesions by providing a pooled proportion of malignant upgrades for VAB/VABB. While it does not directly relate to the previously covered topics of adjuvant chemotherapy, multimodal data integration, ESPB for analgesia, ADC resistance, or beta-blocker therapy for cardiac preservation, it provides specific data on the diagnostic accuracy of VAB/VABB in breast cancer pathology.

When a doctor finds a suspicious lump in the breast, the first step is often a biopsy to see if it is cancerous. Sometimes, these initial tests show a lesion that looks mostly harmless but has a small chance of containing hidden cancer. This is known as a malignant upgrade.

Researchers looked at data from 844 of these specific lesions. They found that about 11.23% of the cases showed a malignant upgrade when a vacuum-assisted biopsy (VAB) was used. This procedure uses a vacuum to help remove a larger piece of tissue for testing. While the results are promising, the evidence is currently considered to be of low certainty because the data came from a limited number of studies.

This finding does not mean the procedure is always better than other methods. Instead, it suggests that VAB can be a helpful tool in a team-based approach. Doctors can use it to get a clearer picture of a lesion before deciding on the next steps for a patient.

What this means for you:
Vacuum-assisted biopsy can help identify hidden cancer in breast lesions that initially appear benign.

Common questions

What is a malignant upgrade in a breast lesion?

A malignant upgrade happens when a breast lesion that looks mostly harmless on initial tests is found to contain cancer upon closer inspection. In this study, about 11.23% of the 844 lesions tested with a vacuum-assisted biopsy showed this kind of upgrade.

How does a vacuum-assisted biopsy work?

A vacuum-assisted biopsy (VAB) uses a vacuum to help remove a larger piece of tissue from a breast lesion. This larger sample can provide a more detailed look at the tissue to see if any hidden cancer is present.

Is this procedure better than other types of biopsies?

The study does not say that vacuum-assisted biopsy is always better than other methods. Instead, it suggests that the procedure is a helpful tool for doctors to use when making decisions about how to treat a patient's specific condition.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedOct 2026
View Original Abstract ↓
Vacuum-assisted breast biopsy (VAB/VABB) and vacuum-assisted excision (VAE) serve distinct diagnostic and therapeutic roles, requiring pathway-specific evaluation of their outcomes. This systematic review reconstructed a report-level and outcome-level dataset from 26 publications, of which 18 were reviewed in full text and 8 remained incompletely retrieved. Reports without complete full text were retained for narrative context but excluded from quantitative synthesis. Five full-text studies contributed 98 malignant upgrades among 844 B3 lesions after diagnostic VAB/VABB. The pooled proportion was 11.23% (95% confidence interval [CI], 7.22%-17.04%; 95% prediction interval [PI], 4.56%-25.06%; I = 60.8%). Three full-text studies of second-line VAE reported study-specific upgrade proportions from 5.1% to 21.4%; these estimates were not pooled because selection pathways and case mix differed substantially. Post-VAE radiologic removal, absence of residual lesion, and recurrence-free outcomes ranged from 86.0% to 99.2% across five full-text cohorts but were not combined because they represented different endpoints and follow-up intervals. Only one fully retrieved study provided reconstructable diagnostic 2 × 2 data, precluding a diagnostic meta-analysis or hierarchical model. Certainty was very low for the principal observational outcomes and low for the single randomized comparison. The evidence supports pathway-specific interpretation and multidisciplinary decision-making, not universal superiority over core needle biopsy or equivalence to surgical excision.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.